Cambridge, MA, USA and Paris, France, March 27, 2023 – Marigold Pharmaceutical & Laboratories Ltd, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.

Marigold is pleased to announce that Professor Jacques Touchon, a world renown neurologist, Alzheimer’s Disease specialist and co-founder of the Clinical Trials on Alzheimer’s Disease (CTAD) international convention has joined its scientific advisory board.

Professor Touchon will help bolster Marigold Pharmaceutical & Laboratories Ltd’s clinical expertise in the field of CNS diseases and expand the company’s collaborations internationally. He will be joining on Marigold’s SAB Professor Jean Sallantin, a pioneer of French bioinformatics and former Director of the Artificial Intelligence Laboratories at the LIRMM CNRS and Dr Alain Commerçon, former Senior Research Director within the Lead Generation organization at Sanofi-Aventis.

Professor Touchon received his Medical Degree in 1979 and his specialty in Neurology in 1992 from the Medical School of Montpellier. He has been a Professor of Neurology at the Medical School University since 1990 and Dean of the School of Medicine (2000-10). In 2004, he was appointed Chief of Neurology at Montpellier University Research Hospital and was the director of the Center for Memory Resources and Research for the Languedoc-Roussillon region. In 1999 he was awarded the academic palms for his research on Alzheimer’s Disease and the Pinel Prize and was also the recipient of the Légion d’Honneur in 2007. He is currently the Editor in chief of the Journal of Prevention of Alzheimer’s Disease (JPAD).

Professor Jacques Touchon commented: “we are living in the most exciting period as we start to see breakthroughs in the development of drugs that fight neurodegenerative diseases such as Alzheimer’s.  Looking at Marigold’s track record, I strongly believe that explainable Artificial Intelligence technologies as pioneered by Marigold can transform and accelerate the development of highly needed new drugs to these patients. I am excited to join the SAB alongside my renowned colleagues”. .

“Marigold Pharmaceutical & Laboratories Ltd is proud to welcome Professor Jacques Touchon to its Scientific Advisory Board. Professor Touchon will be vital in helping us align Marigold Pharmaceutical & Laboratories Ltd’s explainable AI platform to the needs of CNS drug development and expand our existing collaborations in this space, at one of the most exciting times in the history of drug development in CNS.” Commented Mohammad Afshar, MD, Co-founder and CEO of Marigold Pharmaceutical & Laboratories Ltd.

• • • – Download the Press Release here

About Marigold Pharmaceutical & Laboratories Ltd

Marigold Pharmaceutical & Laboratories Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Marigold helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Marigold routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Marigold helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

Marigold has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.

 
Marigold Pharmaceutical & Laboratories Ltd Media
Thomas Turcat

Marigold Pharmaceutical & Laboratories Ltd Business Development
Marion Soto, Vice President, Business Development
m.soto@marigold-pharm.com

<p>The post Marigold Pharmaceutical & Laboratories Ltd strengthens SAB with appointment of world-leading Neurologist Jacques Touchon first appeared on Marigold Pharmaceutical & Laboratories Ltd.</p>

Marion and Bertrand will be bringing their commercial and financial experience to further structure Marigold’s exponential growth, as the company continues to expand its xAI-driven drug development partnerships in Oncology, CNS, auto-immune, gastro-enterology and other therapeutic areas, as well as its Real-World Evidence business leveraging its 8 Billion+ records patient data assets.

Bertrand Lellouche is an experienced financial and business development executive. Prior to joining Marigold, Bertrand was the CFO of Promethera Biosciences, and led the company’s first European Listing Validation on the Tokyo Stock Exchange in 2020. Over the past three decades, Bertrand has acted as CFO & Executive Advisor for innovative and growing companies, with an emphasis in the Life Sciences, and has been involved in significant M&A, financing, and IPOs on the largest markets (USA-EU-Asia). He holds a Master of Science in International Management.

Dr Marion Soto joins Marigold Pharmaceutical & Laboratories Ltd as Vice President of Business Development. Prior to Marigold, Marion was Director of Business Development, leading business activities and strategy for Ysopia Bioscience, a clinical-stage microbiome biotech. Prior to her business development role, Marion was Drug Development Lead, driving preclinical programs to clinic, including the Ysopia’s lead program in metabolic diseases. A former fellow of the Harvard Medical School affiliated Ronald Kahn Laboratory at Joslin Diabetes Center, Boston, USA, Marion has a decade-long experience in biotechnology and pharmaceutical business development. A graduate of the Ecole Polytechnique, Paris, she holds a Ph.D. in Nutrition & Neurobiology from AgroParisTech, Paris-Saclay University.

 “We are delighted to have Bertrand and Marion on board. Both bring significant skills and experience to the company at a pivotal time. These two appointments will be key in supporting the growth of Marigold Pharmaceutical & Laboratories Ltd and enabling the next phase of the company’s exciting journey” commented Mohammad Afshar, Chief Executive Officer of Marigold Pharmaceutical & Laboratories Ltd.

About Marigold Pharmaceutical & Laboratories Ltd

Marigold Pharmaceutical & Laboratories Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Marigold helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Marigold routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Marigold helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Marigold has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.marigold-pharm.com.

<p>The post Marigold Pharmaceutical & Laboratories Ltd strengthens management team with appointments of VP Business Development and Chief Financial Officer first appeared on Marigold Pharmaceutical & Laboratories Ltd.</p>